Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 4Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 3

Study Type

Interventional 7

Sponsor

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Solid Cancer × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

NCT07281326 2025-12-15

A Study of AK138D1 in Advanced Malignant Tumors

Akeso

Phase 1 Recruiting
200 enrolled

Solid Cancer

NCT06730386 2025-03-06

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Akeso

Phase 1 Recruiting
100 enrolled

Solid Cancer

NCT06763159 2025-01-08

A Study of HS-20124 in Patients with Advanced Solid Tumors

Hansoh BioMedical R&D Company

Phase 1 Recruiting
450 enrolled

Solid Cancer

NCT06697665 2024-11-20

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase EARLY_PHASE1 Recruiting
10 enrolled

Solid Cancer

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated
7 enrolled

Solid Cancer

NCT00925743 2013-05-16

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Sanofi

Phase 1 Completed
76 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡